Abstract:Over the past 20 years, the severe acute respiratory syndrome coronavirus (SARS-CoV), Middle East respiratory syndrome CoV (MERS-CoV), and SARS-CoV-2 emerged, causing severe human respiratory diseases throughout the globe. Developing broad-spectrum drugs would be invaluable in responding to new, emerging coronaviruses and to address unmet urgent clinical needs. Main protease (Mpro; also known as 3CL(pro)) has a major role in the coronavirus life cycle and is one of the most important targets for anti-coronavirus agents. We show that a natural product, noncovalent inhibitor, shikonin, is a pan-main protease inhibitor of SARS-CoV-2, SARS-CoV, MERS-CoV, human coronavirus (HCoV)-HKU1, HCoV-NL63, and HCoV-229E with micromolar half maximal inhibitory concentration (IC50) values. Structures of the main protease of different coronavirus genus, SARS-CoV from the betacoronavirus genus and HCoV-NL63 from the alphacoronavirus genus, were determined by X-ray crystallography and revealed that the inhibitor interacts with key active site residues in a unique mode. The structure of the main protease inhibitor complex presents an opportunity to discover a novel series of broad-spectrum inhibitors. These data provide substantial evidence that shikonin and its derivatives may be effective against most coronaviruses as well as emerging coronaviruses of the future. Given the importance of the main protease for coronavirus therapeutic indication, insights from these studies should accelerate the development and design of safer and more effective antiviral agents. IMPORTANCE The current pandemic has created an urgent need for broad-spectrum inhibitors of SARS-CoV-2. The main protease is relatively conservative compared to the spike protein and, thus, is one of the most promising targets in developing anticoronavirus agents. We solved the crystal structures of the main protease of SARSCoV and HCoV-NL63 that bound to shikonin. The structures provide important insights, have broad implications for understanding the structural basis underlying enzyme activity, and can facilitate rational design of broad-spectrum anti-coronavirus ligands as new therapeutic agents.

Recent Progress in the Discovery of Inhibitors Targeting Coronavirus Proteases

Structures of Two Coronavirus Main Proteases: Implications for Substrate Binding and Antiviral Drug Design.

Drug Design Targeting the Main Protease, the Achilles Heel of Coronaviruses

REVISITING THE SARS-COV-2 MAIN PROTEASE: A 2023 IN SILICO ODYSSEY IN SEARCH OF POTENTIAL INHIBITORS

Design of Wide-Spectrum Inhibitors Targeting Coronavirus Main Proteases.

Design of wide-spectrum inhibitors targeting coronavirus main proteases

Progress in Research on Inhibitors Targeting SARS-CoV-2 Main Protease (M pro )

Advances in Enzymatic Activity Regulation Mechanism and Inhibitor Discovery of Coronavirus 3C-Like Protease

Targeting SARS-CoV-2 Proteases for COVID-19 Antiviral Development

Research Progress on Active Compounds Against Pathogenic Coronaviruses and Their Potential Target Proteins

The research progress of SARS-CoV-2 main protease inhibitors from 2020 to 2022

Progress of SARS-CoV-2 Main protease peptide-like inhibitors

Potential of Coronavirus 3C-Like Protease Inhibitors for the Development of New Anti-Sars-cov-2 Drugs: Insights from Structures of Protease and Inhibitors.

Potential molecular targets of nonstructural proteins for the development of antiviral drugs against SARS-CoV-2 infection

Progress of SARS‐CoV‐2 Main Protease Peptide‐like Inhibitors

Discovery of Human Coronaviruses Pan-Papain-like Protease Inhibitors Using Computational Approaches

Targeting the Dimerization of the Main Protease of Coronaviruses: A Potential Broad-Spectrum Therapeutic Strategy

Advances in the Search for SARS-CoV-2 Mpro and PLpro Inhibitors

Protease inhibitors targeting coronavirus and filovirus entry

Development of Novel Antivrial Agents That Induce the Degradation of the Main Protease of Human-infecting Coronaviruses

Structure-Based Discovery and Structural Basis of a Novel Broad-Spectrum Natural Product against the Main Protease of Coronavirus